# Clinical Cases: Pharmacodynamics

## Case 1: Warfarin-Induced Skin Necrosis (Protein C Deficiency)

### Clinical Scenario
A 52-year-old female develops painful skin lesions 4 days after starting warfarin therapy for newly diagnosed deep vein thrombosis.

### Patient Demographics
- **Age:** 52 years
- **Sex:** Female
- **Weight:** 85 kg

### Chief Complaint
Painful, darkening skin patches on thighs and breasts for 24 hours

### History of Present Illness
The patient was diagnosed with left lower extremity deep vein thrombosis 5 days ago and started on warfarin 10 mg daily without heparin bridging. She developed painful, erythematous patches on her bilateral thighs and left breast that have rapidly progressed to purple-black discoloration with blistering.

### Physical Examination
- **Vital Signs:** BP 138/82 mmHg, HR 92 bpm, RR 16, T 37.4C
- **General:** Anxious, in moderate pain
- **Skin:**
  - Bilateral thighs: 8-10 cm areas of violaceous discoloration with central necrosis and surrounding erythema
  - Left breast: 5 cm area of purple-black eschar with bullae
  - Areas are exquisitely tender to palpation
- **Extremities:** Left lower extremity swelling consistent with DVT

### Workup and Results
| Test | Result | Reference Range |
|------|--------|-----------------|
| INR | 3.8 | 2.0-3.0 (therapeutic) |
| Protein C activity | 28% | 70-140% |
| Protein S activity | 85% | 60-150% |
| D-dimer | 4.2 mcg/mL | <0.5 mcg/mL |
| Platelet count | 245,000/mcL | 150,000-400,000/mcL |

**Skin biopsy:** Thrombosis of dermal vessels with overlying epidermal necrosis

### Diagnosis
**Warfarin-induced skin necrosis** due to acquired protein C deficiency in a patient with underlying heterozygous protein C deficiency

### Pharmacodynamic Principles Illustrated
1. **Differential protein half-lives:** Protein C (vitamin K-dependent anticoagulant) has a shorter half-life (8 hours) than clotting factors II and X (60-72 hours).
2. **Transient hypercoagulable state:** Early warfarin therapy depletes protein C before adequate anticoagulation is achieved, creating paradoxical thrombosis.
3. **Therapeutic index:** This adverse effect demonstrates that even drugs within therapeutic range can cause severe harm.
4. **Receptor/pathway effects:** Warfarin affects the vitamin K cycle broadly, impacting both procoagulant and anticoagulant proteins.

### Treatment
1. Immediately discontinue warfarin
2. Administer vitamin K 10 mg IV to reverse warfarin effect
3. Start therapeutic anticoagulation with heparin or LMWH
4. Fresh frozen plasma or protein C concentrate for severe cases
5. Wound care with possible surgical debridement of necrotic tissue
6. Consider alternative anticoagulation (DOAC) for long-term therapy
7. Genetic testing for hereditary protein C deficiency

### Clinical Image

![Warfarin Necrosis](case_01_image.jpg)

*Warfarin-induced skin necrosis showing characteristic violaceous discoloration with central necrosis. This occurs in areas with significant subcutaneous fat (breast, thighs, buttocks) due to microvascular thrombosis.*

**Image Source:** Wikimedia Commons
**License:** CC BY-SA 3.0
**URL:** https://commons.wikimedia.org/wiki/File:Warfarin_necrosis.jpg

---

## Case 2: Sildenafil-Nitrate Drug Interaction (Pharmacodynamic Synergism)

### Clinical Scenario
A 68-year-old male presents to the emergency department with severe hypotension after taking sildenafil and sublingual nitroglycerin.

### Patient Demographics
- **Age:** 68 years
- **Sex:** Male
- **Weight:** 78 kg

### Chief Complaint
Dizziness, near-syncope, and severe weakness for 1 hour

### History of Present Illness
The patient has a history of stable angina and takes isosorbide mononitrate 30 mg daily. He recently obtained sildenafil from an online pharmacy and took 50 mg approximately 3 hours ago. He subsequently developed chest tightness and used sublingual nitroglycerin (0.4 mg) from his prescription. Within minutes, he became extremely dizzy, diaphoretic, and nearly lost consciousness.

### Physical Examination
- **Vital Signs:** BP 68/40 mmHg, HR 110 bpm, RR 20, T 36.5C, SpO2 96% on RA
- **General:** Pale, diaphoretic, appears ill
- **Cardiovascular:** Tachycardic, regular rhythm, no murmurs
- **Neurological:** Alert but lethargic, no focal deficits
- **Skin:** Cool, clammy, pale

### Workup and Results
| Test | Result | Reference Range |
|------|--------|-----------------|
| Troponin I | 0.02 ng/mL | <0.04 ng/mL |
| BNP | 180 pg/mL | <100 pg/mL |
| Creatinine | 1.1 mg/dL | 0.6-1.2 mg/dL |
| Glucose | 145 mg/dL | 70-100 mg/dL |

**ECG:** Sinus tachycardia, no ST changes, no evidence of ischemia

### Diagnosis
**Severe hypotension** due to pharmacodynamic synergism between phosphodiesterase-5 inhibitor (sildenafil) and nitrates

### Pharmacodynamic Principles Illustrated
1. **Synergistic drug interaction:** Sildenafil inhibits PDE5, which breaks down cGMP. Nitrates increase cGMP production. Together, they cause excessive cGMP accumulation and profound vasodilation.
2. **Same pathway, different targets:** Both drugs act on the nitric oxide-cGMP-vasodilation pathway but at different points.
3. **Contraindicated combination:** This is an absolute contraindication due to predictable, severe hypotension.
4. **Duration of interaction:** Sildenafil has a half-life of 4-5 hours, but interaction window extends 24-48 hours.

### Treatment
1. Place patient in Trendelenburg position
2. Aggressive IV fluid resuscitation (normal saline boluses)
3. If refractory, consider vasopressor support (phenylephrine preferred - alpha-1 agonist)
4. Avoid beta-agonists which may worsen hypotension through beta-2 vasodilation
5. Monitor for myocardial ischemia
6. Patient education about dangerous drug interaction
7. Consultation with cardiology regarding alternative angina management

### Clinical Image

![Sildenafil Structure](case_02_image.jpg)

*Chemical structure of sildenafil, a phosphodiesterase-5 inhibitor that prevents degradation of cyclic GMP, potentiating the vasodilatory effects of nitric oxide and nitrate medications.*

**Image Source:** Wikimedia Commons
**License:** Public Domain
**URL:** https://commons.wikimedia.org/wiki/File:Sildenafil.svg

---

## Case 3: Beta-Blocker Withdrawal Syndrome (Receptor Upregulation)

### Clinical Scenario
A 55-year-old male presents with chest pain, palpitations, and severe hypertension 48 hours after abruptly stopping his metoprolol.

### Patient Demographics
- **Age:** 55 years
- **Sex:** Male
- **Weight:** 90 kg

### Chief Complaint
Chest tightness, racing heart, and severe headache for 12 hours

### History of Present Illness
The patient has a history of hypertension and stable angina, controlled on metoprolol succinate 200 mg daily for 8 years. He ran out of medication 3 days ago and could not get a refill due to a pharmacy issue. Over the past 48 hours, he has developed progressive chest tightness, palpitations, anxiety, diaphoresis, and severe headache.

### Physical Examination
- **Vital Signs:** BP 210/115 mmHg, HR 118 bpm, RR 22, T 37.1C
- **General:** Anxious, diaphoretic
- **Cardiovascular:** Tachycardic, regular, no murmurs, hyperdynamic precordium
- **Neurological:** Alert, oriented, no focal deficits
- **HEENT:** Pupils dilated, no papilledema on fundoscopy

### Workup and Results
| Test | Result | Reference Range |
|------|--------|-----------------|
| Troponin I | 0.08 ng/mL | <0.04 ng/mL |
| BNP | 320 pg/mL | <100 pg/mL |
| Creatinine | 1.0 mg/dL | 0.6-1.2 mg/dL |
| TSH | 2.1 mIU/L | 0.4-4.0 mIU/L |

**ECG:** Sinus tachycardia at 118 bpm, 1 mm ST depression in leads V4-V6

### Diagnosis
**Beta-blocker withdrawal syndrome** with rebound hypertension, tachycardia, and demand ischemia due to receptor upregulation

### Pharmacodynamic Principles Illustrated
1. **Receptor upregulation:** Chronic beta-blockade leads to increased beta-receptor density and sensitivity as a compensatory mechanism.
2. **Rebound phenomenon:** Abrupt discontinuation unmasks the upregulated receptors, causing exaggerated response to circulating catecholamines.
3. **Tolerance and dependence:** These are physiological adaptations distinct from addiction.
4. **Tapering requirement:** Gradual dose reduction over 1-2 weeks allows receptor normalization.

### Treatment
1. Immediately restart beta-blocker (IV metoprolol 5 mg, repeat as needed)
2. Aspirin and heparin for possible ACS
3. IV nitroglycerin for persistent hypertension and angina
4. Continuous cardiac monitoring
5. Serial troponins and ECGs
6. Once stabilized, ensure adequate outpatient supply and education about never stopping abruptly

### Key Learning Points
- Beta-blocker withdrawal is a medical emergency in patients with coronary disease
- Can precipitate acute coronary syndrome, arrhythmias, or hypertensive crisis
- Always taper beta-blockers over 1-2 weeks when discontinuing
- Patients should be educated never to stop abruptly and to have adequate medication supply